Leucrose

Synonyms: 5-O-α-D-Glucopyranosyl-D-fructose
Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) 是一种具有口服活性的 Sucrose (MS-J79287) 异构体,天然存在于花粉和蜂蜜中,可促进 JAK1 和 STAT6 的磷酸化,减少促炎介质和细胞因子 (TNFα、IL-1β),增强 M2 巨噬细胞极化并抑制 DSS (MS-A45736) 诱导的结肠炎,同时可抑制高脂饮食诱导的肥胖小鼠肝脏甘油三酯积累,改善空腹血糖水平,并调控肝脏脂肪生成与脂肪酸 β-氧化,此外还可被 α-葡萄糖苷酶 (α-glucosidase) 缓慢水解为葡萄糖和果糖,可作为膳食中的代糖。
产品编号: MS-T47151 纯度: 98.53% CAS No.: 7158-70-5 分子式: C12H22O11 分子量: 342.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in Water
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
250mg
询价
询价
500mg
询价
询价
1g
询价
询价

产品描述

Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) 是一种具有口服活性的 Sucrose (MS-J79287) 异构体,天然存在于花粉和蜂蜜中,可促进 JAK1 和 STAT6 的磷酸化,减少促炎介质和细胞因子 (TNFα、IL-1β),增强 M2 巨噬细胞极化并抑制 DSS (MS-A45736) 诱导的结肠炎,同时可抑制高脂饮食诱导的肥胖小鼠肝脏甘油三酯积累,改善空腹血糖水平,并调控肝脏脂肪生成与脂肪酸 β-氧化,此外还可被 α-葡萄糖苷酶 (α-glucosidase) 缓慢水解为葡萄糖和果糖,可作为膳食中的代糖。

生物实验数据

生物活性 Leucrose (5-O-α-D-Glucopyranosyl-D-fructose) is an orally active isomer of Sucrose (MS-J79287) that naturally occurs in pollen and honey, promotes the phosphorylation of JAK1 and STAT6, reduces pro-inflammatory mediators and cytokines (TNFα, IL-1β), enhances M2 macrophage polarization, and inhibits DSS (MS-A45736)-induced colitis; it also suppresses hepatic triglyceride accumulation in high-fat diet-induced obese mice, improves fasting blood glucose levels, and regulates hepatic lipogenesis and fatty acid β-oxidation, and it can be slowly hydrolyzed by α-glucosidase into glucose and fructose, serving as a dietary sugar substitute.
IC50 & Target

JAK1

 

STAT6

 

IL-1β

 

体外研究
(In Vitro)

Leucrose (24 h) 在含 20 ng/mL 的 IL4 、总葡萄糖浓度为 25 mM 且以 Leucrose 部分替代葡萄糖的 DMEM 培养基中,其相较于葡萄糖处理组,不会改变 RAW 264.7 巨噬细胞的细胞活性,但可上调 RAW 264.7 巨噬细胞中的 M2 型巨噬细胞标志物 (CD163、Arg1),并增强 JAK1/STAT6 的磷酸化水平。
Leucrose 在小肠中经 α- 葡萄糖苷酶水解生成葡萄糖和果糖,并在 3T3-L1 脂肪细胞中抑制脂肪生成、下调脂肪生成相关基因的表达。

Cell Viability Assay

Cell Line: RAW 264.7 macrophage cells
Concentration: 25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
Incubation Time: 24 h
Result: Significantly exceeds levels in the non-treated control group across all treated groups.
Shows no significant difference between leucrose-treated groups (25% and 50% substitution) and the glucose-treated group.

Western Blot Analysis

Cell Line: RAW 264.7 macrophage cells
Concentration: 25% substitution of 25 mM glucose content; 50% substitution of 25 mM glucose content
Incubation Time: 24 h (with 20 ng/mL IL-4)
Result: Increases CD163 levels by 99.0% in the 50% leucrose substitution group compared to the high-glucose control group.
Increases Arg1 levels by 78.6% in the 50% leucrose substitution group compared to the high-glucose control group.
Significantly increases p-JAK1 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.
Significantly increases p-STAT6 levels in both the 25% and 50% leucrose substitution groups compared to the high-glucose control group.
体内研究
(In Vivo)

Leucrose (替代总蔗糖含量的 25-50%;口服;饮食自由摄取;持续 5 周) 补充剂可抑制 DSS 诱导的 C57BL/6 小鼠结肠炎,其中 50% 替代组相较于仅 DSS (MS-A45736) 处理组,可使 DAI AUC0-t 降低 37.3%,结肠长度恢复 20.3%,结肠组织 IL-1β mRNA 水平降低 81.1%,其作用机制为调控炎症介质及 M2 巨噬细胞极化。
Leucrose (替换 25%-50% 的总蔗糖;口服;饮食自由摄取;12 周) 可改善肥胖小鼠的空腹血糖水平,减少肝脏甘油三酯蓄积,下调肝脏脂肪生成相关基因,并上调肝脏 β-氧化相关基因;其中 50%的替换比例在降低肝脏甘油三酯和激活 β-氧化基因方面表现出更强的效力。
Leucrose (饮食占比 25%;口服;每日给药;持续 6 周) 可支持断乳雄性 SPF 级 SD 大鼠的正常生长,其体重增长、蛋白质效率及能量效率与蔗糖或玉米淀粉对照组无统计学差异。

Animal Model: C57BL/6 (male, 5-week-old, 18-20 g, DSS-induced colitis model)
Dosage: 25% of total sucrose content replaced with leucrose; 50% of total sucrose content replaced with leucrose
Administration: p.o.; ad libitum in diet; continuously for 5 weeks
Result: Attenuated DAI scores at day 19 by 59.2% (25% replacement) and 56.9% (50% replacement) compared to the DSS-only group.
Suppressed DAI area under the curve (AUC) scores by 25.4% (25% replacement) and 37.3% (50% replacement) compared to the DSS-only group.
Restored colon length by 12.6% (25% replacement) and 20.3% (50% replacement) compared to the DSS-only group.
Reduced myeloperoxidase (MPO) activity by 30.4% (25% replacement) and 31.9% (50% replacement) compared to the DSS-only group.
Reduced colon tissue iNOS protein levels by 89.3% (50% replacement) and COX2 protein levels by 84.0% (50% replacement) compared to the DSS-only group.
Down-regulated colon tissue mRNA levels of MCP-1, TNFα, and IL-1β by 44.7%, 34.7%, and 81.1% respectively in the 50% replacement group compared to the DSS-only group.
Reduced plasma IL-1β concentrations by 36.9% (25% replacement) and 34.4% (50% replacement) compared to the DSS-only group.
Significantly reduced colon tissue F4/80-positive macrophage infiltration compared to the DSS-only group in both leucrose groups.
Significantly increased colon tissue mRNA levels of M2 polarization markers Arg1 and Ym1 in both leucrose groups, and CD206 in the 50% replacement group only, compared to the DSS-only group.
Animal Model: C57BL/6 (5-week-old male, 18-20 g, high-fat diet-induced obesity model)
Dosage: 25% of total sucrose replaced with leucrose; 50% of total sucrose replaced with leucrose
Administration: p.o.; ad libitum in diet; 12 weeks
Result: Reduced fasting blood glucose levels to 141 mg/dL (L25 group) and 133 mg/dL (L50 group), compared to HFD control's 184 mg/dL.
Reduced hepatic triglyceride content to 70 mg/g in L50 group compared to HFD control; L25 group showed non-significant reduction.
Downregulated peroxisome proliferator-activated receptor γ (Pparg) in L25 and L50 groups; downregulated sterol regulatory element binding protein 1C (Srebf1) in both leucrose groups; fatty acid synthase (Fasn) showed non-significant downward trend.
Upregulated peroxisome proliferator-activated receptor α (Ppara) and acyl CoA oxidase (Acox1) in L50 group; upregulated carnitine palmitoyltransferase 1A (Cpt1a) in both L25 and L50 groups, reversing HFD-induced downregulation.
性状 固体
颜色 White to off-white

化学信息

分子量 342.30
分子式 C12H22O11
CAS No. 7158-70-5
别名 5-O-α-D-Glucopyranosyl-D-fructose

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 70 mg/mL (204.50 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM2.9214 mL14.6071 mL29.2141 mL73.0354 mL
5 mM0.5843 mL2.9214 mL5.8428 mL14.6071 mL
10 mM0.2921 mL1.4607 mL2.9214 mL7.3035 mL
15 mM0.1948 mL0.9738 mL1.9476 mL4.8690 mL
20 mM0.1461 mL0.7304 mL1.4607 mL3.6518 mL
25 mM0.1169 mL0.5843 mL1.1686 mL2.9214 mL
30 mM0.0974 mL0.4869 mL0.9738 mL2.4345 mL
40 mM0.0730 mL0.3652 mL0.7304 mL1.8259 mL
50 mM0.0584 mL0.2921 mL0.5843 mL1.4607 mL
60 mM0.0487 mL0.2435 mL0.4869 mL1.2173 mL
80 mM0.0365 mL0.1826 mL0.3652 mL0.9129 mL
100 mM0.0292 mL0.1461 mL0.2921 mL0.7304 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础